MedCity Pivot Podcast: Modernizing Prior Auth

Why It Matters

Modernizing prior authorization reduces administrative waste, accelerates patient access to therapy, and lowers overall health‑care spending, making it a strategic priority for payers, providers, and employers.

Key Takeaways

• ePA can cut 60‑70% of prior‑auth processing time.
• Standardized APIs (e.g., H‑57, FHIR) drive interoperability across plans.
• Low‑value drug authorizations inflate costs and delay care.
• Amazon Pharmacy offers real‑time visibility similar to package tracking.
• Employers must audit PBM contracts to protect employee benefit experience.

Pulse Analysis

Prior authorization has long been a bottleneck in U.S. healthcare, consuming physician time and inflating administrative expenses. Studies estimate that each authorization costs providers $20‑$30 and adds up to 60‑70% of the total effort spent on medication approval. The delay not only frustrates patients—who may stand at the pharmacy only to learn the drug is not covered—but can also jeopardize clinical outcomes, as illustrated by the seven‑day wait for a cancer patient’s radiation order. Recognizing these harms, CMS has pledged to eliminate fax‑based requests within two years, signaling a regulatory shift toward digital workflows.

Electronic prior authorizations (ePA) and standardized APIs such as H‑57 and FHIR are the technical levers that can deliver that shift. By connecting electronic health records, benefit databases, and pharmacy systems in real time, health plans can evaluate eligibility and clinical criteria without manual paperwork. Companies like Abarca Health are building decision‑tree platforms to prune low‑value rules, while Amazon Pharmacy leverages its logistics expertise to give patients a “track‑your‑prescription” view akin to a delivery service. Early pilots suggest ePA can reduce processing time by up to 70%, freeing clinicians for direct care.

The ripple effects extend to employers and PBMs, who now face heightened scrutiny over transparency and cost‑effectiveness. As benefit designers reassess contracts, modular PBM models that separate pharmacy benefit administration from drug pricing are gaining traction, exemplified by Blue Shield of California’s partnership with Amazon Pharmacy. Consumer expectations for instant updates and same‑day delivery are reshaping acceptable timelines, pressuring the industry to make prior‑auth workflows invisible to both prescribers and patients. Organizations that adopt interoperable standards and eliminate unnecessary authorizations will likely see higher adherence rates and lower total cost of care.